Skip to main content
. 2010 Oct 26;19(1):140–149. doi: 10.1038/mt.2010.224

Figure 3.

Figure 3

CPA modulates immune subsets in vivo. (a) MTT survival assay for AE17ova cells treated with different concentrations of CPA (percentage of control cell survival ± s.d). (b–f) Spleens from tumor-bearing mice treated with PBS, CPA, VSV, or CPA/VSV according to the schedule of Figure 2b, were analyzed by flow cytometry for (b) CD4+ T cells, (c) CD8+ T cells, (d) NK1.1 cells, or (e) CD4+CD25+FoxP3+ Treg. CPA, cyclophosphamide; PBS, phosphate-buffered saline; VSV, vesicular stomatitis virus.